← Back to Search

Monoclonal Antibodies

Camidanlumab Tesirine for Hodgkin's Lymphoma

Phase 2
Waitlist Available
Research Sponsored by ADC Therapeutics S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial will test a new drug, Camidanlumab Tesirine, for people with HL who haven't responded to other treatments. The goal is to see if it's effective and safe.

Eligible Conditions
  • Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Response Rate (ORR)
Secondary outcome measures
AI For Camidanlumab Tesirine PBD-Conjugated Antibody
AI For Camidanlumab Tesirine Unconjugated Warhead SG3199
AUCinf For Camidanlumab Tesirine PBD-Conjugated Antibody
+36 more

Side effects data

From 2023 Phase 2 trial • 117 Patients • NCT04052997
38%
Fatigue
32%
Rash maculo-papular
30%
Pyrexia
27%
Nausea
26%
Rash
25%
Anaemia
24%
Pruritus
21%
Thrombocytopenia
18%
Hypophosphataemia
17%
Constipation
17%
Gamma-glutamyltransferase increased
16%
Diarrhoea
16%
Headache
16%
Arthralgia
16%
Neutropenia
15%
Lymphopenia
14%
Insomnia
14%
Dyspnoea
13%
Alanine aminotransferase increased
12%
Hyperglycaemia
12%
Oedema peripheral
12%
Aspartate aminotransferase increased
12%
Hypokalaemia
12%
Erythema
11%
Vomiting
10%
Hypothyroidism
10%
Abdominal pain
10%
Chills
10%
Decreased appetite
10%
Dizziness
10%
Cough
9%
Blood alkaline phosphatase increased
9%
Myalgia
9%
Oropharyngeal pain
8%
Weight decreased
8%
Amylase increased
8%
Lipase increased
8%
Hypomagnesaemia
7%
Hyperthyroidism
7%
Sinus tachycardia
7%
Asthenia
6%
Peripheral sensory neuropathy
6%
Thyroiditis
6%
Dry mouth
6%
Face oedema
6%
Upper respiratory tract infection
6%
Hyponatraemia
6%
Dry skin
5%
Neuropathy peripheral
5%
Pain in extremity
5%
Dyspepsia
5%
Stomatitis
5%
Dysgeusia
5%
Anxiety
5%
Dehydration
5%
Hypertension
5%
Muscular weakness
3%
Guillain-Barre syndrome
2%
Diabetic ketoacidosis
2%
Cellulitis
2%
Pneumonia
2%
Pneumonitis
1%
Small intestinal obstruction
1%
Acidosis
1%
Peripheral motor neuropathy
1%
Shock haemorrhagic
1%
Tooth infection
1%
Electrolyte imbalance
1%
Inguinal hernia
1%
Adenovirus infection
1%
Bronchopulmonary aspergillosis
1%
Septic shock
1%
Acute kidney injury
1%
Photosensitivity reaction
1%
Intestinal obstruction
1%
Acute respiratory failure
1%
Cancer pain
1%
Bone marrow failure
1%
Febrile neutropenia
1%
Acute myocardial infarction
1%
Cardiac arrest
1%
Left ventricular failure
1%
Myocardial infarction
1%
Duodenal ulcer
1%
Duodenal ulcer perforation
1%
JC virus infection
1%
Lung infection
1%
Pneumonia bacterial
1%
Pneumonia pneumococcal
1%
Rash pustular
1%
Sepsis
1%
Varicella zoster virus infection
1%
Transplant failure
1%
Type 1 diabetes mellitus
1%
Myositis
1%
Epilepsy
1%
Radiculopathy
1%
Syncope
1%
Device occlusion
1%
Tubulointerstitial nephritis
1%
Respiratory failure
1%
Dermatitis exfoliative generalised
1%
Dermatosis
1%
Eczema
1%
Lichenoid keratosis
1%
Parakeratosis
1%
Superior vena cava occlusion
1%
Drug-induced liver injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
Camidanlumab Tesirine

Trial Design

1Treatment groups
Experimental Treatment
Group I: Camidanlumab TesirineExperimental Treatment1 Intervention
Camidanlumab Tesirine is administered as a 30- minute intravenous (IV) infusion on Day 1 of each cycle (every 3 weeks). Camidanlumab Tesirine will be administered at a dose of 45 μg/kg every 3 weeks for 2 cycles, then 30 μg/kg for subsequent cycles.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Camidanlumab Tesirine
2019
Completed Phase 2
~120

Find a Location

Who is running the clinical trial?

ADC Therapeutics S.A.Lead Sponsor
28 Previous Clinical Trials
2,116 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this a pioneering exploration of the subject matter?

"Camidanlumab Tesirine has been under clinical investigation since 2018, when it was first trialled by ADC Therapeutics S.A.. Following the successful completion of Phase 1 in which 95 patients were enrolled, approval for a drug-based intervention was granted. Currently there are 3 live trials being conducted across 11 nations and 30 cities worldwide."

Answered by AI

How many participants is this trial accommodating?

"This research has ceased to recruit participants. It was posted in September of 2019 and last modified in November 2022. If you are interested, there are currently 1723 studies for lymphoma patients seeking volunteers and 3 trials specifically recruiting Camidanlumab Tesirine candidates."

Answered by AI

Is Camidanlumab Tesirine officially sanctioned by the FDA?

"Our team assigned Camidanlumab Tesirine a score of 2 because it has undergone Phase 2 trials, demonstrating some safety but no efficacy yet."

Answered by AI

Has Camidanlumab Tesirine been the subject of any further research?

"Currently, a mere 3 medical trials are actively researching the effects of Camidanlumab Tesirine with none having yet reached phase 3. Durham North carolina is hosting some of these studies while 88 other sites have opened their doors to patient recruitment for this medication."

Answered by AI

Is enrollment currently open for this clinical trial?

"This clinical trial has ended its recruitment phase. Initially posted on September 13th 2019, the protocol was last updated November 11th 2022. Presently, there are 1723 studies recruiting for lymphoma and 3 trials actively searching for Camidanlumab Tesirine patients."

Answered by AI

Are there numerous facilities conducting this research study in the city?

"Patients for this research can be found at The University of Texas Health Science Center, British Columbia Cancer Agency, Princess Margaret Cancer Centre and 27 other sites across the United States and Canada."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
2019. "Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04052997.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top